The Cholesterol Wars: Recent Cholesterol Guidelines and Integration into Clinical Practice

Statin therapy is the recommended treatment for lowering low-density lipoprotein cholesterol (LDL-C) and reducing atherosclerotic cardiovascular disease (ASCVD) risk. However, evidence-based and guideline-recommended therapies, including ezetimibe and PCSK9 inhibitors, continue to be underutilized, even among the highest risk patients. Consequently, an unmitigated burden of cardiovascular risk persists. More education is urgently needed to address this problem. To that end, NATF invites you to join us for a virtual series of webinars that discuss some of these key issues in cholesterol management.

[@kyefang8278]

Back to the basic, why healthy floating LDL-C is considered "bad" at the first place? Does Statin and other medication help reduce the damaged LDL-C? If buoyant LDL-C is not an issue, all the discussions here are meaningless.